Lewis Joel's Form 4 filing
Galectin Therapeutics Inc (GALT) · filed Nov 7, 2025
- Accession no.
- 0001133416-25-000048
- Filed
- Nov 7, 2025
- Trade date
- Nov 5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.20K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JoelCIK 0001725595 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 5, 2025 | Common Stock | MOption exerciseAcquired | +200 | $2.39 | +$478 | 832,792 | Direct | |
| Nov 5, 2025 | Common Stock | SSaleDisposed | −200 | $6.00 | −$1,200 | 832,592 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 5, 2025 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 24,230 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.